NMS-005 - Drug Design and Optimisation at the IL-1 Receptor-Associated Kinase (IRAK)

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: NMS-005
• By: SHOEMAKE, Claire
• Co-author(s): Ms Justine Decelis (University of Malta, Imsida , Malta)
  Dr Claire Shoemake (University of Malta, Imsida , Malta)
  
• Abstract:

  Introduction
  IRAK4 activation is crucial in the pathophysiology of rheumatoid arthritis and progression of tumour growth. Four experimental IRAK4 inhibitors are currently undergoing phase 1 or 2 clinical trials including Emavusertib (CA4948). Although no IRAK4 inhibitors are currently available, successful antagonism of this target is very..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login